Paris, France

Laurent Micouin

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2012

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovator Spotlight: Laurent Micouin

Introduction

Laurent Micouin, a distinguished inventor based in Paris, France, has made significant contributions to the field of pharmaceutical sciences. With one patent to his name, he has focused on creating innovative compounds that hold promise in the fight against cancer.

Latest Patents

Micouin's notable patent is for α-galactoceramide analogs, which involves their methods of manufacture, intermediate compounds useful in these methods, and pharmaceutical compositions containing them. This invention details the synthesis of α-galactoceramide analogs using unsaturated intermediate compounds, enabling a simple metathesis reaction. The resulting analogs are of great relevance as active ingredients in pharmaceutical formulations, particularly those aimed at exhibiting anti-cancer properties.

Career Highlights

Throughout his career, Laurent Micouin has worked with esteemed institutions, including the Centre National de la Recherche Scientifique and Université Paris Descartes. His work has been pivotal in advancing our understanding of pharmaceutical compounds, contributing to both academic knowledge and practical applications.

Collaborations

Micouin has collaborated with notable researchers such as Didier Dubreuil and Muriel Pipelier. These collaborations highlight his commitment to teamwork and the sharing of knowledge, essential traits for innovation in the scientific community.

Conclusion

In conclusion, Laurent Micouin stands out as a key figure in the realm of pharmaceutical inventions. His innovative work on α-galactoceramide analogs not only showcases his ingenuity but also promises advancements in cancer treatment methodologies. His contributions reflect the vital intersection of research and practical application in the health sciences.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…